Mayo study identifies new potential treatment option for triple negative breast cancer

In a recent study published in the Journal of Clinical Investigation, Mayo Clinic researchers identified that an FDA drug approved for myelodysplastic syndrome may be useful to treat triple-negative breast cancer, which is one of the most aggressive and lethal types of breast cancer.

Go to Source

(Visited 11 times, 1 visits today)

Site Footer

Sliding Sidebar